摘要
目的探讨脑卒中后丘脑性疼痛不同治疗方法的临床疗效和安全性。方法65例丘脑痛病人,随机分为2组,联合治疗组采用度洛西汀胶囊40mg·d-1联合甲钴胺片1500μg·d-1治疗(n=33),对照组单独应用度洛西汀胶囊40mg·d-1治疗(n=32)。共观察4wk。以视觉模拟评分(VAS)和临床治愈率作为疗效评估指标。结果度洛西汀联用甲钴胺的VAS治疗前后有显著差异(7.5±s1.2vs4.8±0.9,P<0.01);对照组治疗前后无显著差异(7.4±1.1vs6.8±1.3,P>0.05),2组治疗后VAS有显著差异(P<0.01)。联合治疗组临床治愈22例,治愈率67%;对照组临床治愈11例,治愈率34%,2组有显著差异(χ2=6.78,P<0.01)。2组各有4例发生不良反应,组间无显著差异(P>0.05)。结论度洛西汀联用甲钴胺治疗丘脑痛的疗效优于度洛西汀单药治疗。
AIM To evaluate the safety and efficacy of different therapeutic effect of thalamic pain after stroke. METHODS Sixty-five patients with thalamic pain were randomly divided into two group： 33 patients received the combined treatment with duloxetine capsule 40 mg·d^-1 and mecobalamin tablets 1 500μg ·d^-1 （combined-treatment group）, and 32 patients of controls received duloxetine capsule 40 mg· d^-1 （control group）. RESULTS There was significant difference in visual analogue scale （VAS） of the combined-treatment group before and after the treatment （7.5 ± s 1.2 vs 4.8 ± 0.9, P 〈 0.01） with no difference in the control group （7.4 ±1.1 vs 6.8 ± 1.3, P 〉 0.05）. There was significant difference in VAS and clinical cure rate （67% vs 34%） between the two group after the treatment （P 〈 0.01）. The adverse reactions rate of the combined-treatment group and the control group was 12% and 12%, respectively （P 〉 0.05）. CONCLUSION The curative effect of combined treatment with duloxetine and mecobalamin is better than that of duloxetine single used.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2009年第7期523-525,共3页
Chinese Journal of New Drugs and Clinical Remedies
关键词
脑血管意外
甲钴胺
度洛西汀
随机对照试验
丘脑痛
cerebrovascular accident
mecobalamin
duloxetine
randomized controlled trails
thalamic pain
